Publicacions destacades

A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

Perez-Amill, Lorena; Armand-Ugon, Mercedes; Val-Casals, Maria; Martin-Herreros, Beatriz; Alamo, Jose R;

(...)

Urbano-Ispizua, Alvaro; Montesinos, Pau; Delgado, Julio; Juan, Manel; Klein-Gonzalez, Nela.

Referència:
LEUKEMIA 2025.
Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Uribe-Herranz, Mireia; Oliver-Caldes, Aina; Martinez-Micaelo, Neus; Espanol-Rego, Marta; Val-Casals, Maria;

(...)

Pascal, Mariona; Urbano-Ispizua, Alvaro; Gonzalez-Navarro, Europa Azucena; Fernandez de Larrea, Carlos; Juan, Manel.

Referència:
Blood Cancer Discov 2025.
A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Falgas, Aida; Lazaro-Gorines, Rodrigo; Zanetti, Samanta Romina; Rubio-Perez, Laura; Martinez-Moreno, Alba;

(...)

Delgado, Julio; Orfao, Alberto; Alvarez-Vallina, Luis; Bueno, Clara; Menendez, Pablo.

Referència:
BLOOD 2025.
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

Rea, Anna; Santana-Hernandez, Sara; Villanueva, Javier; Sanvicente-Garcia, Marta; Cabo, Mariona;

(...)

Montagut, Clara; Albanell, Joan; Guell, Marc; Lopez-Botet, Miguel; Muntasell, Aura.

Referència:
NATURE IMMUNOLOGY 2025.
New models for the development of and access to CART-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis

Pearson, Andrew D J; Rossig, Claudia; Mackall, Crystal L; Shah, Nirali N; Baruchel, Andre;

(...)

Ktasian, Sarah; Weigel, Brenda; Weiner, Susan; Zwaan, C Michel; Vassal, Gilles.

Referència:
LANCET ONCOLOGY 2025.
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

Bachiller, Mireia; Barcelo-Genestar, Nina; Rodriguez-Garcia, Alba; Alserawan, Leticia; Dobano-Lopez, Celia;

(...)

Juan, Manel; Delgado, Julio; Perez-Galan, Patricia; Urbano-Ispizua, Alvaro; Guedan, Sonia.

Referència:
MOLECULAR THERAPY 2025.
Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.

Oliver-Caldes, A; Español-Rego, M; Zabaleta, A; González-Calle, V; Navarro-Velázquez, S;

(...)

Mateos, MV; Urbano-Ispizua, A; Paiva, B; Pascal, M; de Larrea, CF.

Referència:
CLINICAL CANCER RESEARCH 2024.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

Díez-Alonso, L; Falgas, A; Arroyo-Ródenas, J; Romencín, PA; Martínez, A;

(...)

Martín-Antonio, B; Orfao, A; Menéndez, P; Bueno, C; alvarez-Vallina, L.

Referència:
Science Translational Medicine 2024.
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma

Martínez-Cibrián, N; Ortiz-Maldonado, V; Español-Rego, M; Blázquez, A; Cid, J;

(...)

López-Guillermo, A; Pascal, M; Urbano-Ispizua, A; Juan, ME; Delgado, J.

Referència:
BRITISH JOURNAL OF HAEMATOLOGY 2024.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CART-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA- HCB-01): a single-arm, multicentre, academic pilot study

Oliver-Caldés, A; González-Calle, V; Cabañas, V; Español-Rego, M; Rodríguez-Otero, P;

(...)

Moraleda, JM; Mateos, MV; Pascal, M; Urbano-Ispizua, A; de Larrea, CF.

Referència:
LANCET ONCOLOGY 2023.